NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

A day in the life of misleading drug promotions by pharma

Posted By

Categories

Tags

These were all in the news yesterday.

• FDA warns Novartis about two websites that the FDA says “are concerning from a public health perspective because they promote Gleevec for an unapproved use, fail to disclose the risks associated with the use of Gleevec, and make unsubstantiated dosing claims about this medication that can put patients at higher risk of experiencing serious adverse events.”

• U.S. regulators have warned Roche Holding AG unit Genentech and Shire Plc about misleading promotions for cancer and bowel drugs.

• Novartis AG will pay $72.5 million to settle U.S. Justice Department allegations it submitted false claims for off-label uses of a cystic-fibrosis drug.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.